About the Authors

Daniel B Costa

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

Balázs Halmos

Affiliation University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States of America

Amit Kumar

Affiliation Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

Susan T Schumer

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

Mark S Huberman

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

Titus J Boggon

Affiliation Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

Daniel G Tenen

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

Susumu Kobayashi

To whom correspondence should be addressed. E-mail: skobayas@bidmc.harvard.edu

Affiliation Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

DBC conducted the experiments and analyzed the clinical and experimental data. AK and TJB generated the structural model of EGFR with secondary mutations and edited the manuscript. STS and MSH contributed to the clinical care, sample collection, and data acquisition of the gefitinib-resistant patients. BH and DGT supervised all aspects of this study including study design, execution, and interpretation. SK designed and conducted the experiments and analyzed the clinical and experimental data. DBC, BH, DGT and SK wrote the final manuscript.